Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Extraordinary General Meeting

Wed, 10/05/2022 - 12:00
Notice187.37 KB
Proxy279.32 KB
Shareholders' rights pursuant to art. 7:130 and 7:139 of the Belgian Companies Code28.39 KB
Remuneration policy212.93 KB
Special Report of Board of Directors pursuant to art. 7:199 of the Belgian Companies Code76.28 KB
Special Report of Board of Directors pursuant to art. 7:179 and 7:197 of the Belgian Companies Code141.76 KB
Document Valuation1.43 MB
Auditor's report pursuant to art. 7:179 and 7:197 of the Belgian Companies Code (FR)411.18 KB
Special Report of Board of Directors pursuant to art. 7:180, 7:191 and 7:193 of the Belgian Companies Code89.87 KB
Auditor's report pursuant to art. 7:180, 7:191 and 7:193 of the Belgian Companies Code (FR)400.15 KB
Terms and Conditions of the Subscription Rights99.82 KB
CV Directors : Jean-François Rax88.57 KB
CV Directors : François Rieger99.62 KB
CV Directors : Revital Rattenbach85.83 KB
CV Directors : Terry Sadler78.28 KB
CV Directors : Véronique Pomi79.09 KB
Year
2022
Financial Information
Annual General Meeting
Shareholder information
Shareholder meetings
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions